PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,771.50
Bid: 1,771.00
Ask: 1,771.50
Change: -12.00 (-0.67%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

12 Sep 2017 16:07

RNS Number : 5501Q
GlaxoSmithKline PLC
12 September 2017
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

 

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

   

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

   

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHELLFFDKFBBBE
Date   Source Headline
12th Apr 20219:48 amRNSDirector/PDMR Shareholding
9th Apr 20215:34 pmRNSDirector/PDMR Shareholding
9th Apr 20211:35 pmRNSDirector/PDMR Shareholding
6th Apr 20212:30 pmRNSDirectorate Change
1st Apr 20213:36 pmRNSTotal Voting Rights
30th Mar 20214:21 pmRNSPublication of 2021 AGM Notice
30th Mar 202111:30 amRNSGSK respiratory product sales reporting changes
24th Mar 202112:30 pmRNSMoncef Slaoui Departs Galvani Bioelectronics
23rd Mar 20214:31 pmRNSDirector/PDMR Shareholding
17th Mar 20216:24 pmRNSChair of Audit & Risk Committee
16th Mar 202111:08 amRNSMedicago and GSK start Phase 3 trial
15th Mar 20215:27 pmRNSDirector/PDMR Shareholding
15th Mar 20217:00 amRNSAnnual Report 2020 on Form 20-F
11th Mar 20212:25 pmRNSDirector/PDMR Shareholding
11th Mar 20217:00 amRNSGSK and Vir share positive VIR-7831 data in COVID
10th Mar 20211:23 pmRNSDirector/PDMR Shareholding
9th Mar 20211:43 pmRNSAnnual Financial Report
2nd Mar 20213:48 pmRNSDirector/PDMR Shareholding
1st Mar 202110:55 amRNSTotal Voting Rights
25th Feb 202112:00 pmRNSGSK announces otilimab data for treatment of COVID
24th Feb 20211:59 pmRNSDirector/PDMR Shareholding
24th Feb 202112:13 pmRNSHolding(s) in Company
23rd Feb 20219:03 amRNSDirector/PDMR Shareholding
22nd Feb 20214:39 pmRNSDirector/PDMR Shareholding
22nd Feb 202110:40 amRNSSanofi and GSK initiate new Phase 2 study
19th Feb 202112:52 pmRNSDirector/PDMR Shareholding
19th Feb 202112:31 pmRNSDirector/PDMR Shareholding
19th Feb 202110:32 amRNSDirector/PDMR Shareholding
18th Feb 20219:59 amRNSDirector/PDMR Shareholding
17th Feb 202112:00 pmRNSGSK/Vir collaborate on antibodies for influenza
17th Feb 20219:00 amRNSDirector/PDMR Shareholding
15th Feb 202110:09 amRNSDirector/PDMR Shareholding
15th Feb 20219:15 amRNSDirector/PDMR Shareholding
12th Feb 20214:26 pmRNSDirector/PDMR Shareholding
12th Feb 20214:23 pmRNSDirector/PDMR Shareholding
12th Feb 20214:20 pmRNSDirector/PDMR Shareholding
10th Feb 20215:05 pmRNSDirector/PDMR Shareholding
10th Feb 20214:54 pmRNSDirector/PDMR Shareholding
4th Feb 202111:15 amRNSDirector/PDMR Shareholding
3rd Feb 202112:00 pmRNSFinal Results
3rd Feb 20217:00 amRNSGSK/CureVac partner on new mRNA Covid-19 vaccines
1st Feb 20212:04 pmRNSTotal Voting Rights
26th Jan 20214:26 pmRNSDirector/PDMR Shareholding
22nd Jan 20217:00 amRNSFDA approves ViiV Healthcare’s Cabenuva for HIV
20th Jan 20214:00 pmRNSDirector/PDMR Shareholding
20th Jan 20213:50 pmRNSDirector/PDMR Shareholding
20th Jan 20213:02 pmRNSDirector/PDMR Shareholding
19th Jan 20216:02 pmRNSDirector/PDMR Shareholding
15th Jan 20214:00 pmRNSDirector/PDMR Shareholding
15th Jan 20213:14 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.